Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.
| Revenue (TTM) | $2.78B |
| Gross Profit (TTM) | $2.01B |
| EBITDA | $611.20M |
| Operating Margin | 20.80% |
| Return on Equity | 162.10% |
| Return on Assets | 20.10% |
| Revenue/Share (TTM) | $98.47 |
| Book Value | $15.54 |
| Price-to-Book | 39.70 |
| Price-to-Sales (TTM) | 6.31 |
| EV/Revenue | 6.05 |
| EV/EBITDA | 27.56 |
| Quarterly Earnings Growth (YoY) | 37.10% |
| Quarterly Revenue Growth (YoY) | 17.20% |
| Shares Outstanding | $27.91M |
| Float | $22.66M |
| % Insiders | 18.77% |
| % Institutions | 90.74% |
Volatility is currently expanding
Investors interested in Medical Services stocks are likely familiar with Concentra Group (CON) and Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
In the latest trading session, Medpace (MEDP) closed at $609.89, marking a -1.64% move from the previous day.
Medpace Holdings is misunderstood due to its faster, cleaner backlog burn, which the market misinterprets as a growth ceiling rather than a quality upgrade. Q2 revenues rose 17.2% to $707.3M, with EBITDA margin improving beneath headline pass-through cost effects; guidance for FY26 was raised across revenue, EBITDA, and EPS. Customer prepayments fund operations and share buybacks, supporting EPS growth and providing a buffer against potential cash flow volatility as biotech funding rebounds.
Medpace (MEDP) concluded the recent trading session at $602.9, signifying a -2.84% move from its prior day's close.
In the closing of the recent trading day, Medpace (MEDP) stood at $622.11, denoting a +1% move from the preceding trading day.
Investors with an interest in Medical Services stocks have likely encountered both Concentra Group (CON) and Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its third quarter 2026 financial results after the market close on Wednesday, October 21, 2026. The Company will host a conference call the following morning, Thursday, October 22, 2026, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended yo.
Medpace (MEDP) concluded the recent trading session at $624.2, signifying a +1.94% move from its prior day's close.
In the latest trading session, Medpace (MEDP) closed at $595.41, marking a +1.34% move from the previous day.
Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Medpace (MEDP). But which of these two stocks is more attractive to value investors?
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MEDP and any ticker you trade — then tracks every position and per-strategy win rate.
